Shire (LON:SHP)‘s stock had its “buy” rating reissued by analysts at Societe Generale in a research report issued to clients and investors on Wednesday, March 14th. They presently have a GBX 7,500 ($105.28) target price on the biopharmaceutical company’s stock. Societe Generale’s price objective indicates a potential upside of 102.24% from the company’s previous close.
SHP has been the subject of a number of other research reports. JPMorgan Chase lowered shares of Shire to a “neutral” rating and lowered their price target for the company from GBX 5,000 ($70.19) to GBX 3,600 ($50.53) in a report on Tuesday, February 20th. HSBC lowered their target price on shares of Shire from GBX 4,050 ($56.85) to GBX 3,800 ($53.34) and set a “hold” rating for the company in a report on Tuesday, November 21st. Deutsche Bank reaffirmed a “buy” rating on shares of Shire in a report on Monday, December 11th. Citigroup reaffirmed a “buy” rating and set a GBX 5,500 ($77.20) target price on shares of Shire in a report on Friday, January 5th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a GBX 5,700 ($80.01) target price on shares of Shire in a report on Friday, December 1st. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of GBX 4,650 ($65.27).
Shares of LON SHP traded up GBX 1.50 ($0.02) during mid-day trading on Wednesday, hitting GBX 3,708.50 ($52.06). The company had a trading volume of 3,081,841 shares, compared to its average volume of 3,140,000. Shire has a 12 month low of GBX 2,940.50 ($41.28) and a 12 month high of GBX 5,021 ($70.48).
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/08/shire-shp-earns-buy-rating-from-societe-generale.html.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.